Tri Locum Partners LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Tri Locum Partners LP reported 25 stock positions worth $395.5 million. Its top holding was Teva Pharmaceutical-SP ADR (TEVA) at 10.5% of the portfolio, followed by Argenx SE - ADR (ARGX, 8.1%) and Ascendis Pharma A/S (ASND, 7.9%). Compared with Q1 2024, it opened 10 new positions, sold out of 12, added to 12 and reduced 2. The biggest buy was a new position in Amgen (AMGN) and the biggest sale an exit from Silk Road Medical (SILK).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001826434
- Portfolio Value
- $395.5M (Q2 2024)
- SEC Filing
- 0001826434-24-000006 ↗ filed Aug 14, 2024
Holdings Value
Holdings 25 stocks · $395.5M
| TEVA Teva Pharmaceutical-SP ADR | 10.48% | 2,550,307 | $41.4M | Add +15.1% |
| ARGX Argenx SE - ADR | 8.11% | 74,558 | $32.1M | Add +166.5% |
| ASND Ascendis Pharma A/S | 7.85% | 227,762 | $31.1M | Add +102.2% |
| AMGN Amgen Inc. | 6.50% | 82,271 | $25.7M | New |
| NTRA Natera Inc. | 6.31% | 230,585 | $25.0M | Add +21.3% |
| AXSM Axsome Therapeutics Inc. | 6.24% | 306,513 | $24.7M | Add +198.4% |
| INSM Insmed Inc. | 5.36% | 316,501 | $21.2M | New |
| MRUS Merus NV | 5.02% | 335,514 | $19.9M | Add +17.2% |
| REGN Regeneron Pharmaceuticals | 4.65% | 17,516 | $18.4M | Add +104.5% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.63% | 65,352 | $18.3M | Add +22.5% |
| INSP Inspire Medical Systems Inc. | 4.51% | 133,276 | $17.8M | Add +465.5% |
| AVDL Avadel Pharmaceuticals plc | 4.23% | 1,189,518 | $16.7M | Add +0.0% |
| PFE Pfizer Inc. | 4.22% | 596,919 | $16.7M | New |
| UTHR United Therapeutics Corp. | 4.04% | 50,100 | $16.0M | New |
| LEGN Legend Biotech Corp.-ADR | 3.99% | 356,532 | $15.8M | Add +25.6% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.76% | 45,000 | $10.9M | New |
| STVN Stevanato Group SPA | 2.62% | 565,422 | $10.4M | New |
| NVO Novo-Nordisk A/S-Spons ADR | 2.30% | 63,811 | $9.1M | New |
| PCVX Vaxcyte Inc. | 2.16% | 113,344 | $8.6M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.01% | 101,959 | $4.0M | Reduce -50.9% |
| OCUL Ocular Therapeutix Inc. | 0.89% | 514,642 | $3.5M | New |
| PRAX Praxis Precision Medicines I | 0.79% | 75,319 | $3.1M | Reduce -29.3% |
| MIND MEDICINE MINDMED INC | 0.70% | 382,055 | $2.8M | Add +0.7% |
| KRRO Korro Bio Inc. | 0.61% | 71,428 | $2.4M | New |
| FEMY Femasys Inc. | 0.01% | 30,606 | $35K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| SILK Silk Road Medical Inc. | Sold out | 0.00% | −6.88 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −5.45 |
| VRTX Vertex Pharmaceuticals Inc. | Sold out | 0.00% | −5.16 |
| BAX Baxter International Inc. | Sold out | 0.00% | −4.71 |
| TNDM Tandem Diabetes Care Inc. | Sold out | 0.00% | −4.01 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −2.16 |
| LYRA Lyra Therapeutics Inc. | Sold out | 0.00% | −2.11 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -50.9% | 1.01% | −2.09 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −1.80 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −1.66 |
| ARCT Arcturus Therapeutics Holdin | Sold out | 0.00% | −1.63 |
| ARQT Arcutis Biotherapeutics Inc. | Sold out | 0.00% | −1.55 |
| PRAX Praxis Precision Medicines I | Reduce -29.3% | 0.79% | −1.47 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.32 |
Portfolio Buys Q1 2024 → Q2 2024
| AMGN Amgen Inc. | New | 6.50% | +6.50 |
| INSM Insmed Inc. | New | 5.36% | +5.36 |
| ARGX Argenx SE - ADR | Add +166.5% | 8.11% | +4.29 |
| PFE Pfizer Inc. | New | 4.22% | +4.22 |
| UTHR United Therapeutics Corp. | New | 4.04% | +4.04 |
| AXSM Axsome Therapeutics Inc. | Add +198.4% | 6.24% | +3.40 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 2.76% | +2.76 |
| INSP Inspire Medical Systems Inc. | Add +465.5% | 4.51% | +2.75 |
| STVN Stevanato Group SPA | New | 2.62% | +2.62 |
| NVO Novo-Nordisk A/S-Spons ADR | New | 2.30% | +2.30 |
| PCVX Vaxcyte Inc. | New | 2.16% | +2.16 |
| ASND Ascendis Pharma A/S | Add +102.2% | 7.85% | +1.95 |
| REGN Regeneron Pharmaceuticals | Add +104.5% | 4.65% | +1.80 |
| OCUL Ocular Therapeutix Inc. | New | 0.89% | +0.89 |
| KRRO Korro Bio Inc. | New | 0.61% | +0.61 |
| MRUS Merus NV | Add +17.2% | 5.02% | +0.55 |
| NTRA Natera Inc. | Add +21.3% | 6.31% | +0.28 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +22.5% | 4.63% | −0.31 |
| TEVA Teva Pharmaceutical-SP ADR | Add +15.1% | 10.48% | −0.37 |
| MIND MEDICINE MINDMED INC | Add +0.7% | 0.70% | −0.54 |
| LEGN Legend Biotech Corp.-ADR | Add +25.6% | 3.99% | −1.53 |
| AVDL Avadel Pharmaceuticals plc | Add +0.0% | 4.23% | −2.74 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $813.2M | JNJ, VRTX, LLY, ASND, DXCM |
| Q1 2026 | 17 | $712.5M | JNJ, ISRG, TMO, ASND, VRTX |
| Q4 2025 | 15 | $770.1M | JNJ, DHR, LLY, UTHR, ASND |
| Q3 2025 | 18 | $435.1M | JNJ, UTHR, MRK, AXSM, ASND |
| Q2 2025 | 23 | $329.5M | TEVA, MDGL, ALNY, ARGX, ASND |
| Q1 2025 | 22 | $194.9M | CI, MCK, SLNO, TEVA, INSP |
| Q4 2024 | 28 | $482.7M | TEVA, ZBH, ARGX, NTRA, INSP |
| Q3 2024 | 20 | $417.4M | PFE, TEVA, NTRA, STVN, ARGX |
| Q2 2024 | 25 | $395.5M | TEVA, ARGX, ASND, AMGN, NTRA |
| Q1 2024 | 27 | $288.4M | TEVA, AVDL, SILK, NTRA, ASND |